The World Health Organization on Wednesday recommended the widespread use of RTS,S/AS01 malaria vaccine the first-ever vaccine for malaria, one of the oldest known diseases that kills over 4 lakh people annually.
The decision followed a review of a pilot programme deployed since 2019 in Ghana, Kenya and Malawi in which more than two million doses were given of the vaccine, first made by the pharmaceutical company GSK in 1987.
WHO said it was “recommending the broad use of the world’s first malaria vaccine”, the agency’s director general Tedros Adhanom Ghebreyesus said.
WHO said it was recommending children in sub-Saharan Africa and in other regions with moderate to high malaria transmission get four doses up to the age of two.
Every two minutes, a child dies of malaria, the agency said. More than half of malaria deaths worldwide are in six sub-Saharan African countries and almost a quarter are in Nigeria alone, according to 2019 WHO figures.
Symptoms include fever, headaches and muscle pain, then cycles of chills, fever and sweating.
Findings from the vaccine pilot showed it “significantly reduces severe malaria which is the deadly form by 30 percent,” said Kate O’Brien, Director of WHO’s Department of Immunization, Vaccines and Biologicals.
The vaccine is “feasible to deliver”, she added and “it’s also reaching the unreached… Two thirds of children who don’t sleep under a bed net in those countries are now benefiting from the vaccine.”
Many vaccines exist against viruses and bacteria but this was the first time that the WHO recommended for broad use a vaccine against a human parasite. The vaccine acts against plasmodium falciparum one of five malaria parasite species and the most deadly. “From a scientific perspective this is a massive breakthrough,” said Pedro Alonso, Director of the WHO Global Malaria Programme.
